Towards Healthcare
Aflibercept Biosimilars Market Leads USD 1.68 Bn in 2025

Aflibercept Biosimilars Market 2025 Trends in Retinal Care

Projections indicate that, the global aflibercept biosimilars market will increase from USD 1.54 billion in 2024 to USD 3.7 billion by 2034, experiencing a CAGR of 9.14% over the next 10 years. The maturing ophthalmic biosimilar ecosystem is estimated to drive the growth of the market in the near future. The national health systems and tender-based procurement models in Europe actively drive biosimilar uptake to reduce healthcare costs.

Content

  • Insight Code: 6125
  • No. of Pages: 150+
  • Format: PDF/PPT/Excel
  • Published: September 2025
  • Report Covered: [Revenue + Volume]
  • Historical Year: 2021-2022
  • Base Year: 2023
  • Estimated Years: 2024-2033

About The Author

Kesiya Chacko is an accomplished market research professional with over 4+ years of experience in the healthcare industry, known for delivering actionable insights and strategic analysis that empower healthcare organizations to navigate complex, rapidly evolving markets.

Kesiya began her research career with Precedence Research, where she built a strong foundation in pharmaceutical and healthcare market analysis. Today, she plays an integral role at Towards Healthcare, contributing to in-depth, client-centric research initiatives. She also brings her expertise to Statifacts, supporting broader research functions with a focus on cross-sector healthcare trends and data interpretation.

Her commitment to high-quality analysis, combined with a strong grasp of regulatory and market dynamics, makes her a trusted contributor to healthcare firms seeking future-ready, data-backed decisions. Kesiya’s work spans the analysis of industry trends, competitive benchmarking, and evaluation of regulatory and innovation-driven shifts.

Talk to us
FAQ's

The aflibercept biosimilars market is valued at USD 1.68 billion in 2025 and is on track to reach USD 3.7 billion by 2034, witnessing a steady CAGR of 9.14% during the forecast span.

Europe is leading the aflibercept biosimilars market due to the growing prevalence of retinal disorders, a strong regulatory framework, and the presence of advanced infrastructure to support manufacturing.

The aflibercept biosimilars market includes six segments including by development type, by therapeutic indication, by route of administration, by end-user, by distribution channel, and by region.

Key trends include the growing need for biologics, advancements in manufacturing technology, initiatives by regulatory bodies and government, and rising adoption of inorganic growth strategies.

The intravitreal injection route is the most common, while novel delivery methods like sustained-release implants are emerging as fast-growing alternatives.

International Generic and Biosimilar Medicines Association, Personalized Medicine Coalition, Association for Accessible Medicines (AAM), Government of Canada, IGBA - International Generic and Biosimilar medicines, Food and Drug Administration, clinicaltrials.gov, Spanish Association of Biosimilars, GOV.UK
Any Questions